All News
Xeljanz Warnings on Shingles Updated by FDA
The MedWatch June 2015 safety labeling changes were published yesterday, and updated the warnings for Xeljanz (tofacitinib). "The risk of herpes zoster is increased in patients treated with Xeljanz and appears to be higher in patients treated with Xeljanz in Japan."
Read ArticlePost-Translationally Modified Proteins as Potential New Early Arthritis Activity Markers
Defects in protein citrullination and its consequences in patients with RA have been studied widely in the recent decade. It appears that autoantibodies, including those against citrullinated proteins, are of diagnostic and prognostic relevance.
Read Article
FDA Strengthens MI and CVA Risks Associated with NSAIDs
FDA announced yesterday they would strengthen warnings stating that non-aspirin nonsteroidal anti-inflammatory drugs increase the chance of a heart attack or stroke. This applies to both prescription and OTC NSAIDs.
Read ArticleDoes ACPA Increase the Risk of Interstitial Lung Disease?
The anti-citrullinated peptide (anti-CCP or ACPA) antibody assay has a specificity of greater than 90% for rheumatoid arthritis and is associated with worse articular outcomes.
Read Article
Neurologic Events with TNF Inhibitor Therapy
Demyelinating disorders are an uncommon complication of TNF inhibition and have been described with all TNF inhibitors but also with other biologics.
Read Article
Adalimumab Drug Levels Predict Efficacy
In a prospective study of 311 rheumatoid arthritis patients starting either adalimumab (ADA) or etanercept, investigators sought to correlate drug levels and/or anti-drug antibodies with clinical outcomes (citation source http://url.ie/z237).
Read Article
Obesity Drives Rheumatoid Arthritis
Systematic review of the literature examined whether obesity is associated with a higher risk of rheumatoid arthritis (citation source http://url.ie/z1y6) and found that obese individuals (BMI > 30) are at
Read Article
Utility of Drug Levels and Anti-Drug Antibodies When Starting TNF inhibitors
A prospective cohort of 331 patients tested for anti-adalimumab (n=160) and anti-etanercept (n-171) antibodies after initiation of their TNF inhibitor therapy.
Read Article
Adherence to ETN/MTX is Greater Than Triple DMARD Therapy
Rheumatoid management hinges on choosing your best therapies first.
Read Article
The History of Citrullination
1998 marked the introduction of citrulline as a unique target in the pathogenesis of rheumatoid arthritis. The hallmark article by Schellekens et al in the Journal of Clinical Investigation has since been cited over 500 times. Dr.
Read Article
Brain Natriuretic Peptide Measurement in Rheumatoid Arthritis
Cardiovascular (CV) risk and adverse cardiac outcomes are common in rheumatoid arthritis (RA). It has been presumed that chronic systemic inflammation has a deleterious effect on the myocardium and vasculature, thereby leading to higher rates of MI, CHF and CV death.
Read Article
Thiazide Diuretics May Reduce Osteoporotic Fracture Risk
A large Swedish cohort study of hypertensive men and women presented at the 25th Scientific Meeting of the European Society of Hypertension, identitied a protective effect on osteoporotic fractures among current users of thiazide diuretic drugs independent of blood pressure level. This retr
Read Article
Frequency of Infliximab Infusion Reactions
A Canadian registry shows that in community-based infusion clinics, infusion reactions to IFX are uncommon and mild to moderate in nature.
Read Article
Cosmic Etiology to RA and Polymyalgia Rheumatica
Researchers at Johns Hopkins, Mayo Clinic and the NIH have determined that solar cycles and geomagnetic effects may account for the incidence of RA and PMR.
Read Article
Expanding Global Biosimilar Market
Between 2010 and 2013, $95 billion in branded pharmaceutical patents will have expired, leading to significantly higher sales opportunities for those manufacturing generics and biosimilars.
Read Article
The EULAR 2015 Report- Friday
These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.
Read Article
The EULAR 2015 Report - Wednesday
EULAR 2015 started the afternoon of Wednesday June 10th.
Read Article
Rheumatic Manifestations of Chikungunya Virus
Chikungunya is a new viral cause of fever and arthritis, especially in endemic areas like the caribbean. The chikungunya epidemic has grown significantly in the Western hemisphere with a total of 1,247,000 cases and 183 fatalities since
Read Article
High Flare Rates with Drug Withdrawal in JIA
While many adult rheumatologists are able to lessen or withdraw DMARD and biologic therapy in adults, little is known about the success of this practice in pediatric rheumatology clinics.
Read Article
Knee Implant Forecast from 2012 - 2018
The global knee implants market was USD 8.4 billion in 2011, and it's forecasted to reach USD 15 billion in 2018, with compound annual growth rate of 8.64% during 2011 to 2018. The U.S.
Read Article